Earnings call transcript: Teva's Q2 2025 shows steady growth, stock rises
PositiveFinancial Markets
Teva Pharmaceuticals reported steady growth in its Q2 2025 earnings call, leading to a rise in its stock price. This positive performance highlights the company's resilience in a challenging market and reflects effective management strategies. Investors are optimistic about Teva's future prospects, making this news significant for stakeholders and the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System











